Direkt zum Inhalt
Merck
  • Endophthalmitis caused by streptococcal species: clinical settings, microbiology, management, and outcomes.

Endophthalmitis caused by streptococcal species: clinical settings, microbiology, management, and outcomes.

American journal of ophthalmology (2014-01-15)
Ajay E Kuriyan, Kathleen D Weiss, Harry W Flynn, William E Smiddy, Audina M Berrocal, Thomas A Albini, Darlene Miller
ZUSAMMENFASSUNG

To report the clinical settings, antibiotic susceptibilities, and outcomes of endophthalmitis caused by Streptococcus species. Retrospective, observational case series. Single-center study evaluating all patients with culture-positive endophthalmitis caused by Streptococcus species between January 1, 2000, and December 31, 2011. Study criteria were met by 63 patients. The most common clinical settings were bleb associated (n = 17; 27%), after intravitreal injection (n = 16; 25%), and after cataract surgery (n = 13; 21%). The isolates were Streptococcus viridans (n = 47; 71%), Streptococcus pneumoniae (n = 13; 21%), and β-hemolytic Streptococci (n = 5; 8%). Sixty (95%) of 63 isolates were susceptible to vancomycin, 47 (98%) of 48 isolates were susceptible to ceftriaxone (third-generation cephalosporin), and 57 (93%) of 61 isolates were susceptible to levofloxacin (third-generation fluoroquinolone). Between the first and second half of the study, the minimal inhibitory concentration of antibiotics required to inhibit 90% of isolates increased by 1.5-fold for ceftriaxone and 2-fold for levofloxacin and remained the same for vancomycin. Initial treatment was vitreous tap (49; 78%) or pars plana vitrectomy (14; 22%); all received intravitreal antibiotics. Visual acuity outcomes were variable: best-corrected visual acuity was 20/400 or better in 16 (25%) patients and worse than 20/400 in 47 (75%) patients. Evisceration or enucleation was performed in 16 (25%) patients. Streptococcus isolates generally had high susceptibility rates to commonly used antibiotics. Higher antibiotic minimal inhibitory concentrations were required to inhibit 90% of isolates in vitro in the second half of the study period compared with the first half. Despite prompt treatment, most patients had poor outcomes.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Vancomycin -hydrochlorid aus Streptomyces orientalis, ≥900 μg per mg (as vancomycin base)
Sigma-Aldrich
Vancomycin -hydrochlorid aus Streptomyces orientalis, ≥85% (Vancomycin B)
Sigma-Aldrich
Vancomycin -hydrochlorid aus Streptomyces orientalis, BioReagent, suitable for plant cell culture
Sigma-Aldrich
Amikacin Hydrat, aminoglycoside antibiotic
Sigma-Aldrich
Amikacin -disulfat (Salz), potency: 674-786 μg per mg (as amikacin base)
USP
Ceftazidim Pentahydrat, United States Pharmacopeia (USP) Reference Standard
Ceftazidim, European Pharmacopoeia (EP) Reference Standard
Vancomycin -hydrochlorid, European Pharmacopoeia (EP) Reference Standard
Millipore
Vancomycin-Supplement, suitable for microbiology
Sigma-Aldrich
Vancomycin -hydrochlorid aus Streptomyces orientalis, meets USP testing specifications
Amikacin, European Pharmacopoeia (EP) Reference Standard
Amikacin -sulfat, European Pharmacopoeia (EP) Reference Standard
Amikacin für die Systemeignung, European Pharmacopoeia (EP) Reference Standard
Ceftazidim für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard